Application of glycine in acute alcohol hallucinosis

Hum Psychopharmacol. 2005 Dec;20(8):591-4. doi: 10.1002/hup.735.

Abstract

Introduction: Previous studies showed that patients with acute alcohol hallucinosis had significantly lower levels of the inhibitory amino acid neurotransmitter, glycine.

Methods: A placebo-controlled, double-blind study of glycine in 40 patients with acute alcohol hallucinosis. Treatment duration was 7 days with no other psychotropic medication.

Results: The 20 patients randomised to the active drug (700 mg glycine sublingually) demonstrated a significant decrease in severity of hallucinosis compared to the 20 patients receiving placebo.

Conclusion: The positive effects of glycine may be related to an altered balance between excitatory and inhibitory amino acid neurotransmitters.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Sublingual
  • Adult
  • Alcoholism / complications
  • Double-Blind Method
  • Drug Administration Schedule
  • Glycine / administration & dosage
  • Glycine / therapeutic use*
  • Glycine Agents / administration & dosage
  • Glycine Agents / therapeutic use
  • Hallucinations / drug therapy*
  • Hallucinations / etiology
  • Humans
  • Male
  • Patient Selection
  • Tablets
  • Treatment Outcome

Substances

  • Glycine Agents
  • Tablets
  • Glycine